Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach

The Lancet Psychiatry

Volumn 3, Issue 10, 2016, Pages 935-946

  Koutsouleris, Nikolaos ^a   Kahn, René S ^b   Chekroud, Adam M ^c,d   Leucht, Stefan ^e   Falkai, Peter ^a   Wobrock, Thomas ^f,g   Derks, Eske M ^b   Fleischhacker, Wolfgang W ^h   Hasan, Alkomiet ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c YALE UNIVERSITY   (United States)

^d YALE NEW HAVEN HOSPITAL   (United States)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f Darmstadt Dieburg Clinics   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL DECISION MAKING; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; FUNCTIONAL DISEASE; HOSPITAL READMISSION; HUMAN; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT-REPORTED OUTCOME; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; REMISSION; TREATMENT DURATION; UNEMPLOYMENT; CLINICAL TRIAL; CONTROLLED STUDY; MULTICENTER STUDY; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CLINICAL DECISION-MAKING; FEMALE; HUMANS; MACHINE LEARNING; MALE; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 84994065541     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(16)30171-7     Document Type: Article

References (35)

1. 1 Freyhan, FA, Course and outcome of schizophrenia. Am J Psychiatry 112 (1955), 161–169.
2. 2 Häfner, H, an der Heiden, W, The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 249:suppl 4 (1999), 14–26.
3. 3 Rössler, W, Salize, HJ, van Os, J, Riecher-Rössler, A, Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15 (2005), 399–409.
4. 4 Harvey, PD, Heaton, RK, Carpenter, WT Jr, Green, MF, Gold, JM, Schoenbaum, M, Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res 140 (2012), 1–8.
5. 5 Crump, C, Winkleby, MA, Sundquist, K, Sundquist, J, Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 170 (2013), 324–333.
6. 6 Kane, JM, Correll, CU, Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71 (2010), 1115–1124.
7. 7 Mourao-Miranda, J, Reinders, AATS, Rocha-Rego, V, et al. Individualized prediction of illness course at the first psychotic episode: a support vector machine MRI study. Psychol Med 42 (2012), 1037–1047.
8. 8 Ventura, J, Subotnik, KL, Guzik, LH, et al. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res 132 (2011), 18–23.
9. 9 Tsang, HW, Leung, AY, Chung, RC, Bell, M, Cheung, W-M, Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry 44 (2010), 495–504.
10. 10 Jääskeläinen, E, Juola, P, Hirvonen, N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 39 (2013), 1296–1306.
11. 11 Noble, WS, What is a support vector machine?. Nat Biotechnol 24 (2006), 1565–1567.
12. 12 Passos, IC, Mwangi, B, Kapczinski, F, Big data analytics and machine learning: 2015 and beyond. Lancet Psychiatry 3 (2016), 13–15.
13. 13 Koutsouleris, N, Riecher-Rössler, A, Meisenzahl, EM, et al. Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr Bull 41 (2015), 471–482.
14. 14 Chekroud, AM, Zotti, RJ, Shehzad, Z, et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 3 (2016), 243–250.
15. 15 Chekroud, AM, Krystal, JH, Personalised pharmacotherapy: an interim solution for antidepressant treatment?. BMJ, 350, 2015, h2502.
16. 16 Correll, CU, Kishimoto, T, Kane, JM, Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci 13 (2011), 155–172.
17. 17 Kahn, RS, Fleischhacker, WW, Boter, H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 (2008), 1085–1097.
18. 18 Scott, J, Leboyer, M, Hickie, I, et al. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry 202 (2013), 243–245.
19. 19 Amminger, GP, Schäfer, MR, Schlögelhofer, M, Klier, CM, McGorry, PD, Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun, 6, 2015, 7934.
20. 20 Torgalsbøen, A-K, Rund, BR, Lessons learned from three studies of recovery from schizophrenia. Int Rev Psychiatry 14 (2002), 312–317.
21. 21 Ruschhaupt, M, Huber, W, Poustka, A, Mansmann, U, A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol, 3, 2004, Article37.
22. 22 Troyanskaya, O, Cantor, M, Sherlock, G, et al. Missing value estimation methods for DNA microarrays. Bioinformatics 17 (2001), 520–525.
23. 23 Guyon, I, Elisseeff, A, An introduction to variable and feature selection. J Mach Learn Res 3 (2003), 1157–1182.
24. 24 König, IR, Malley, JD, Weimar, C, Diener, H-C, Ziegler, A, German Stroke Study Collaboration. Practical experiences on the necessity of external validation. Stat Med 26 (2007), 5499–5511.
25. 25 Derks, EM, Fleischhacker, WW, Boter, H, Peuskens, J, Kahn, RS, EUFEST Study Group. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?. J Clin Psychopharmacol 30 (2010), 176–180.
26. 26 Austin, SF, Mors, O, Secher, RG, et al. Predictors of recovery in first episode psychosis: The OPUS cohort at 10 year follow-up. Schizophr Res 150 (2013), 163–168.
27. 27 Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 (2013), 951–962.
28. 28 Malla, A, Payne, J, First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophr Bull 31 (2005), 650–671.
29. 29 Koutsouleris, N, Davatzikos, C, Bottlender, R, et al. Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification. Schizophr Bull 38 (2012), 1200–1215.
30. 30 Hasan, A, Falkai, P, Wobrock, T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13 (2012), 318–378.
31. 31 Jakubovski, E, Carlson, JP, Bloch, MH, Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. J Clin Psychiatry 76 (2015), 1535–1545.
32. 32 Möller, HJ, Jäger, M, Riedel, M, Obermeier, M, Strauss, A, Bottlender, R, The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: assessing courses, types and time stability of diagnostic classification. Eur Psychiatry 26 (2011), 231–243.
33. 33 Buckley, PF, Miller, BJ, Lehrer, DS, Castle, DJ, Psychiatric comorbidities and schizophrenia. Schizophr Bull 35 (2009), 383–402.
34. 34 Cannon, TD, Cadenhead, K, Cornblatt, B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 65 (2008), 28–37.
35. 35 Michel, C, Ruhrmann, S, Schimmelmann, BG, Klosterkötter, J, Schultze-Lutter, F, A stratified model for psychosis prediction in clinical practice. Schizophr Bull 40 (2014), 1533–1542.